# Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

> **NCT06762808** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT06762808
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-05-01
- **Primary completion:** 2025-08-08
- **Final completion:** 2025-08-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762808, "Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06762808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*